Thus, the totality of the data obtained indicates that rTcCathL1 is an effective peptidase capable of hydrolyzing immunogenic gliadin peptides and can be used to develop a drug for the enzyme therapy of various types of gluten intolerance, as well as for processing raw materials or preparing gluten-free food products from wheat, rye, and barley. This evidence concerns the gene LAP3 and celiac disease.